

Allergan plc  
Form SD  
May 31, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM SD**

**Specialized Disclosure Report**

**ALLERGAN PLC**

**(Exact name of registrant as specified in its charter)**

<b>Ireland</b> <b>(State or other jurisdiction of</b>	<b>001-36867</b> <b>(Commission</b>	<b>98-1114402</b> <b>(IRS Employer</b>
<b>incorporation or organization)</b>	<b>File Number)</b>	<b>Identification No.)</b>

**Clonshaugh Business and Technology Park** **D17 E400**

**Coolock, Dublin, Ireland**

**(Address of principal executive offices)** **(Zip Code)**

**A. Robert D. Bailey**

**EVP & Chief Legal Officer and Corporate Secretary (862) 261-7000**

**(Name and telephone number, including area code, of the person to contact in connection with this report.)**

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017.

**Section 1 Conflict Minerals Disclosure**

**Item 1.01 Conflict Minerals Disclosure and Report**

**Conflict Minerals Disclosure**

This Form SD of Allergan plc (the Company ) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934 for the reporting period January 1, 2017 to December 31, 2017.

A copy of the Company s Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD and is publicly available on Allergan s website at <https://www.allergan.com/investors/financial-information/sec-filings>.

**Item 1.02 Exhibit**

As specified in Section 2, Item 2.01 of this Form SD, the Company is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this report.

**Section 2 Exhibits**

**Item 2.01 Exhibits**

The following exhibit is filed as part of this report.

<b>Exhibit No.</b>	<b>Description</b>
1.01	Conflict Minerals Report of Allergan plc

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

Allergan plc  
By: /s/ A. Robert D. Bailey  
A. Robert D. Bailey

May 31, 2018

*EVP & Chief Legal Officer and Corporate Secretary*

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
1.01	Conflict Minerals Report of Allergan plc